论文部分内容阅读
目的探讨同步放化疗在中晚期宫颈癌治疗中应用的安全性及临床疗效。方法 586例中晚期宫颈癌患者作为研究对象。其中单纯接受放疗的患者291例作为对照组,接受同步放化疗治疗患者295例作为观察组,观察两组患者放化疗治疗效果及不良反应发生情况。结果观察组患者治疗后总缓解率达98.98%,与对照组患者的97.94%比较差异无统计学意义(P>0.05);观察组患者5年生存率、局部复发率、远处转移率明显优于对照组,差异具有统计学意义(P<0.05);观察组患者骨髓移植、消化道反映等不良反应发生率明显高于对照组,差异有统计学意义(P<0.05)。结论同步放化疗用于治疗中晚期宫颈癌可有效提高患者5年生存率,但患者治疗后骨髓移植、消化道反应发生率较高,临床应根据患者实际病情及需求选择适宜的方案治疗。
Objective To investigate the safety and clinical efficacy of concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Methods 586 cases of advanced cervical cancer patients as the research object. Among them, 291 patients received radiotherapy alone as the control group and 295 patients received concurrent chemoradiotherapy as the observation group. The radiotherapy and chemotherapy treatment effects and adverse reactions were observed in both groups. Results The total remission rate of the observation group was 98.98%, which was not significantly different from that of the control group (97.94%) (P> 0.05). The 5-year survival rate, local recurrence rate and distant metastasis rate of the observation group were significantly better The difference was statistically significant (P <0.05). The incidence of adverse reactions such as bone marrow transplantation and gastrointestinal reaction in the observation group was significantly higher than that in the control group (P <0.05). Conclusions Simultaneous chemoradiotherapy for the treatment of advanced cervical cancer can effectively improve the 5-year survival rate of patients. However, the incidence of bone marrow transplantation and digestive tract reaction after treatment is high. Patients should be treated according to the actual conditions and needs.